Nicole Murphy insider trades: Biogen (BIIB) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nicole reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | BIIB | ↑ Buy | 3 | $195.03 | $585 | Direct | Feb 17, 2026 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BIIB insiders
Open-market trades in the last 12 months
About Nicole Murphy's insider trades
Nicole Murphy is Head of Pharm Ops and Tech at Biogen (BIIB). Since Feb 12, 2026, Nicole has reported 1 open-market purchase worth $585 and no sales on SEC Form 4. In the last 12 months: 1 buy ($585).
Their filings also include option exercises (15 filings), shares withheld for taxes (15 filings), grants and awards (7 filings), other transactions (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BIIB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.